X

Trial Profile

Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia (STIM).

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imatinib (Primary) ; Dasatinib; Nilotinib
Indications Chronic myeloid leukaemia
Focus Therapeutic Use
Acronyms STIM

Most Recent Events

20 Jan 2017 Results published in the Journal of Clinical Oncology
08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com